Presence of paraoxonase in human interstitial fluid  by Mackness, Michael I et al.
FEBS 19391 FEBS Letters 416 (1997) 377-380 
Presence of paraoxonase in human interstitial fluid 
Michael I. Mackness*, Bharti Mackness, Sharon Arrol, Grahame Wood, Deepak Bhatnagar, 
Paul N. Durrington 
University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9 WL, UK 
Received 10 September 1997 
Abstract Human serum paraoxonase (PONI) is postulated to 
have anti-atherosclerotic properties through its ability to prevent 
lipid peroxide generation on LDL. However, in order to perform 
this role it must be present in interstitial fluid, to prevent LDL 
oxidation which takes place in the sub-intimal space of the artery 
wall. The PONI activity in interstitial fluid was 15.7 (2.3-183.0) 
(median (range)) nmol/min/ml compared to 105.3 (74.6-323.9) 
nmol/min/ml in serum. The PONI concentration in interstitial 
fluid was found to be 20.2 (1.1-78.1) μ /^ml (median (range)) 
compared to 109.6 (11.1-485.7) μg/ml in serum. Interstitial fluid 
PONI concentration was dependent on the interstitial fluid apo 
AI concentration (r = 0.690, P< 0.005) indicating PONI 
remained associated with HDL. However, the ratio of PONI 
concentration to apo AI was lower in interstitial fluid 
(0.60 ± 0.20) than in the serum (0.95 ± 0.18) (P < 0.001) indicat-
ing sequestration of PONI in the sub-intimal space. Therefore, 
PONI is present and active in interstitial fluid where it can 
perform its anti-atherosclerotic function. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Human serum paraoxonase (aryldialkylphosphatase, 
E.C.3.1.8.1, PONI) is located on high-density lipoprotein 
(HDL) and is associated with its anti-oxidative activity [1-
3]. PONI can prevent lipid peroxide accumulation on low-
density lipoprotein (LDL) [1,2,4] by a mechanism which is 
postulated to involve the hydrolysis of LDL phospholipid 
hydroperoxides [2,4,5]. The oxidative modification of LDL 
by lipid peroxidation is a pro-inflammatory reaction believed 
to be centrally involved in the initiation and propagation of 
atherosclerosis [6]. It is therefore believed that PONI is an 
important determinant of the anti-inflammatory/anti-athero-
sclerotic action of HDL [1-5]. 
We have previously shown that PONI accumulates in the 
human artery wall as atherosclerosis progresses [7]. LDL ox-
idation is believed to occur on particles sequestered in the sub-
intimal space of the artery wall where there is a deficiency in 
anti-oxidant defences [8]. HDL is present in the interstitial 
fluid at a much higher concentration than LDL [9] and is 
therefore, in an ideal position to protect LDL (and perhaps 
cell membranes) from oxidative modification through the ac-
tion of its associated enzymes including PONI [10]. The pur-
pose of the present investigation was to determine whether 
PONI was present in the interstitial fluid of healthy subjects 
and what factors determined its concentration. 
"■Corresponding author. Fax: +44 (161) 274 4833. 
2. Material and methods 
2.1. Subjects 
Sixteen healthy subjects (7 female, 9 male) aged 25-50 years took 
part in the study. All subjects gave informed consent and the study 
was approved by the Central Manchester Health Authority Research 
Ethical Committee. 
Tissue fluid was obtained by a suction blister technique, previously 
described in detail and shown to be a good surrogate for interstitial 
fluid [11]. Venous blood was taken at the same time and serum and 
plasma prepared by centrifugation at 3000 Xg, 4°C for 15 min. White 
cells were taken from the buffy coat of the plasma tube. Interstitial 
fluid and serum were stored in aliquots at —80°C for subsequent 
analysis. 
2.2. Lipid and apolipoprotein analysis 
VLDL, LDL and HDL were isolated from plasma by sequential 
ultracentrifugation [12]. 
Total cholesterol, VLDL, LDL and HDL cholesterol were deter-
mined by the CHOD-PAP enzymatic method (Biostat, Stockport, 
UK). Triglycerides were determined by the GPO-PAP enzymatic 
method (Biostat, Stockport, UK). Free cholesterol was analysed by 
an enzymatic method (Boehringer-Mannheim, Lewes, Sussex). Apoli-
poproteins (apos) AI and В were determined by rate immunonephe-
lometric techniques on the Beckman Array, using standards and con-
trols provided by the manufacturer (Beckman Instruments, Palo Alto, 
USA). 
2.2.1. PONI genotype. DNA was extracted from the white cells 
and PONI genotype for both the 55 and 192 polymorphisms deter-
mined by PCR amplification and restriction enzyme digestion as de-
scribed [13,14]. 
2.2.2. PONI activity. The rate of hydrolysis of paraoxon (5.5 mM 
in 100 mM Tris/HCl buffer containing 2 mM CaCl2 pH 8.0) was 
determined by a continuous spectrophotometric method at 405 nm 
as previously described [15]. 
2.2.3. PONI concentration. Serum PONI concentration was de-
termined by an ELISA method utilising rabbit anti-human PONI 
monospecific polyclonal antisera as described previously [16,17]. 
2.2.4. Statistical analysis. The statistical significance of differences 
between parameters with a gaussian distribution were sought by Stu-
dent's i-test and between parameters with a non-gaussian distribution 
by the Mann-Whitney U test. Pearson's r was used to determine the 
strength of correlation between parameters. 
3. Results 
The serum lipid and lipoprotein concentrations of the sub-
jects are shown in Table 1. In all cases, as expected, the con-
centration in the interstitial fluid was much less than in the 
serum. The concentration of both apo AI and apo В in the 
interstitial fluid were related to their serum concentrations, 
r = 0.656, P<0 .01 for apo AI and r = 0.504, P<0.05 for 
apo B. However, there was no such relationship between se-
rum and interstitial fluid total cholesterol, free cholesterol and 
triglyceride. 
The PONI activity in interstitial fluid was 15.7 (2.3-183.0) 
nmol/min/ml (median (range)) which was 15% of that found 
in serum (105.3 (74.6-323.9) nmol/min/ml) (Table 1). PONI 
activity in interstitial fluid was not correlated with any of the 
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Fig. 1. PONI concentration in interstitial fluid (IFPON) and serum 
(SEPON). PONI concentration was determined in interstitial fluid 
and serum by our specific ELISA as described in Section 2. Length 
of boxes indicates the minimum and maximum values. The bar indi-
cates the mean value. 
other interstitial fluid or serum parameters investigated. The 
PONI concentration in serum was related to the concentra-
tion of apo AI (r = 0.727, P< 0.001). The PONI concentra-
tion in interstitial fluid (20.2 (1.1-78.1)) μ^ιηΐ (median 
(range)) was 20% of that found in serum (109.6 (11.1-
485.7)) μg/ml (P< 0.001) (Fig. 1) and the two concentrations 
were correlated (r = 0.560, P< 0.025) (Fig. 2a). PONI concen-
tration in interstitial fluid was also related to the concentra-
tion of apo AI in the interstitial fluid (r = 0.690, P< 0.005) 
(Fig. 2b) but not to the concentration of serum HDL choles-
terol or PONI. However, the ratio of PONI concentration to 
apo AI was lower in interstitial fluid (0.60 ±0.20) than in the 
serum (0.95±0.18) (P<0.001). The interstitial fluid:serum 
ratio of the concentration of apo AI was 0.29 ±0.05 and 
was significantly higher than that of PONI which was 
0.18 ± 0.04 (P< 0.05) (Fig. 3). 
The PONI genotype distributions in the study subjects were 
44% AA and 56% AB for the 192 polymorphism and 6% 
MM, 56% LM and 38%o LL for the 55 polymorphism. Some 
studies have indicated a relationship between the genetic poly-
morphisms of PONI and plasma lipids and lipoproteins. 
However, none of the interstitial fluid parameters measured 
were affected by either of the polymorphisms. 
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Fig. 2. a: Correlation between PONI concentration in interstitial 
fluid (IFPON) and serum (SEPON). b: Correlation between intersti-
tial fluid PONI (IFPON) and Apo AI (IFAPOAI) concentrations. 
Multiple regression analysis to determine which factors de-
termine the interstitial fluid concentration of PONI and which 
included as co-variables all the lipid and lipoprotein parame-
ters listed in Table 1 and additionally serum PONI concen-
tration, age, gender and the PON-55 and 192 genotypes in-
dicated that the concentration of interstitial fluid apo AI was 
responsible for 37% of the variation in interstitial fluid PONI 
concentration (P < 0.025). None of the other parameters sig-
nificantly accounted for variation in the PONI concentration 
in interstitial fluid. 
Table 1 
Serum lipid, lipoprotein and apolipoprotein concentrations in serum and interstitial fluid of the study subjects 
Serum Interstitial fluid 
Total cholesterol (mmol/1) 
Triglyceride (mmol/1) 
Free cholesterol (mmol/1) 
VLDL cholesterol (mmol/1) 
LDL cholesterol (mmol/1) 
HDL cholesterol (mmol/1) 
Apolipoprotein AI (mg/dl) 
Apolipoprotein В (mg/dl) 
Paraoxonase activity (nmol/min/ml) 
5.61 ±1.32 
1.5710.76 
1.45 ±0.50 
0.4010.24 
4.3710.82 
1.7410.52 
115.8122.2 
91.7129.8 
105.3 (74.6-323.9) 
0.9210.22* 
0.19 + 0.08* 
0.2310.10* 
ND 
ND 
ND 
33.8 + 11.3* 
2.2 + 0.08* 
15.7* (2.3-183.0) 
Serum and interstitial fluid lipids and lipoproteins were analysed in the 16 subjects as described in Section 2. 
*Significantly different from serum concentration P< 0.001. 
ND = Not determined. 
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Fig. 3. Ratio of concentration of Apo AI and PONI in interstitial 
fluid and serum. Values are mean and error bars represent the 
standard deviation. 
4. Discussion 
PONI was first shown by us to reduce LDL lipid peroxi-
dation in vitro [1,2] a finding which has subsequently been 
confirmed and extended by others [4,5]. This has led to a 
postulated role for PONI as an anti-atherosclerotic agent in 
vivo. It is proposed that the pro-atherogenic modifications of 
LDL take place in the sub-intimal space of the artery wall in 
areas poor in anti-oxidant defences [8]. HDL is present in the 
artery wall at a much higher concentration than LDL [9] and 
should, therefore, be ideally placed to protect LDL from ox-
idative modification. However, in order for PONI to be anti-
atherogenic it must retain its association with HDL on pass-
ing from the blood to the interstitial fluid, where it can protect 
LDL from pro-atherogenic modifications. In this investigation 
we have shown that PONI is present in interstitial fluid in an 
active form. We have previously shown that the PONI geno-
type influences activity towards paraoxon [18] and lipid per-
oxides [19]. In this study, the amino acid substitutions did not 
affect the transfer of PONI to interstitial fluid or is sequestra-
tion in the sub-intimal space. 
PONI in serum is associated with a specific HDL sub-spe-
cies also containing apo AI and clusterin [20]. It has been 
suggested that this particle may play a major role in protect-
ing cell membranes and lipoproteins from oxidative damage 
due to the presence of PONI and clusterin [10]. Clusterin has 
been postulated to protect cell membranes from oxidative 
damage by binding to and removing damaged membrane lip-
ids [21]. Using immunohistochemical techniques we have pre-
viously shown that PONI, apo AI and clusterin are present in 
the normal human artery wall and that immunostaining for 
PONI greatly increases as atherosclerosis develops [7] provid-
ing circumstantial evidence for the involvement of the PON1-
HDL particle in atherogenesis, perhaps as a reaction to the 
oxidative element in the process. In the present study, the 
ratio of the concentrations of PONI to apo AI fell from 
0.95 in serum to 0.60 in the interstitial fluid. This indicates 
either a loss of PONI from HDL particles in the interstitial 
fluid or sequestration of the minor sub-fraction of HDL which 
contains PONI. Using crossed immunoelectrophoresis PONI 
was only associated with mature a migrating HDL and not 
pre-ß HDL (result not shown). The proportion of apo AI 
present in pre-ß HDL is greater in interstitial fluid than in 
serum but this difference is probably not large enough to 
account for the change in the PONI :apo AI ratio found in 
this investigation. An alternative explanation is provided by 
our earlier findings using immunohistochemistry of the human 
artery wall which indicated that a significant amount of PONI 
staining could be found on the membranes and within lyso-
somes of smooth muscle cells [7]. This would indicate that a 
significant amount of the PONI-HDL has a physical associ-
ation with tissue (where it could be protecting cell membranes 
and/or undergoing degradation) and will not be detected in 
the tissue fluid. This may also explain why there was no rela-
tionship between PONI concentration in interstitial fluid and 
that in the serum. 
In conclusion the results presented here indicate that PONI 
is present in the interstitial fluid and that a major determinant 
of its concentration is the interstitial fluid apo AI concentra-
tion. It is therefore evident that the association between PONI 
and HDL found in serum [22] remains at least as HDL passes 
into the interstitial fluid and that PONI in interstitial fluid is 
available to prevent the oxidative modification of LDL and 
perform its postulated anti-atherogenic and anti-inflammatory 
role. 
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